Disposition of 22272 shares by White William Richard of Akero Therapeutics at 7.009 subject to Rule 16b-3
AKRO Stock | USD 31.77 0.96 2.93% |
About 57% of Akero Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Akero Therapeutics suggests that many traders are alarmed. Akero Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Akero Therapeutics. Many technical investors use Akero Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Akero |
Filed transaction by Akero Therapeutics Officer: Chief Financial Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Cash Flow Correlation
Akero Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Akero Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Akero Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Akero Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Akero Therapeutics Historical Investor Sentiment
Investor biases related to Akero Therapeutics' public news can be used to forecast risks associated with an investment in Akero. The trend in average sentiment can be used to explain how an investor holding Akero can time the market purely based on public headlines and social activities around Akero Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Akero Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Akero Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Akero Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Akero Therapeutics.
Akero Therapeutics Fundamental Analysis
We analyze Akero Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Akero Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Akero Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Target Price
Target Price Comparative Analysis
Akero Therapeutics is currently under evaluation in target price category among its peers.
Akero Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Akero Therapeutics stock to make a market-neutral strategy. Peer analysis of Akero Therapeutics could also be used in its relative valuation, which is a method of valuing Akero Therapeutics by comparing valuation metrics with similar companies.
Peers
Akero Therapeutics Related Equities
MCRB | Seres Therapeutics | 15.58 | ||||
SCPH | Scpharmaceuticals | 1.79 | ||||
MIST | Milestone Pharmaceuticals | 0.54 | ||||
LUMO | Lumos Pharma | 0.23 | ||||
ELYM | Eliem Therapeutics | 2.60 | ||||
HCWB | HCW Biologics | 20.78 |
Check out Akero Therapeutics Hype Analysis, Akero Therapeutics Correlation and Akero Therapeutics Performance. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.78) | Return On Assets (0.23) | Return On Equity (0.36) |
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.